Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT06585410
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cemiplimab — DRUGAdministered per protocol
- Standard of care — PROCEDUREPrimary surgery
Study Details
This study will test a study drug called cemiplimab to see if it can help treat early-stage Cutaneous Squamous Cell Carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called Programmed cell Death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works compared to surgery
Key Dates
- Start date
- Jan 2, 2025
- Status verified
- May 2026
- Primary completion
- May 3, 2030
- Completion
- May 3, 2030
Study Design
- Enrollment
- 369 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Experimental Arm
- Other: Control Arm
Primary Outcome Measure
Event-Free Survival (EFS) as assessed by the investigator [ Time Frame: Up to 1 year ]
Central Contacts
- Clinical Trials Administrator844-734-6643
Locations (45)
Find similar trials in Phoenix, AZ
By research site
Medical Dermatology Specialists - Phoenix· Phoenix, AZMayo Clinic - Arizona· Scottsdale, AZUniversity of Arizona Cancer Center· Tucson, AZArkansas Research Trials· North Little Rock, ARUC San Diego Moores Cancer Center· La Jolla, CAProfound Research, Dermatology Medical Group - Oceanside· Oceanside, CA
Related Studies
- A Study of VET3-TGI in Patients With Solid TumorsPHASE1 · Recruiting · KaliVir Immunotherapeutics · Los Angeles, California
- Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell CarcinomaRecruiting · University of California, San Francisco · San Francisco, California
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative ExcisionEARLY_PHASE1 · Recruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant RecipientsEARLY_PHASE1 · Recruiting · Marissa Lobl · Pittsburgh, Pennsylvania